2-benzyl-6-methyl-2,3-dihydropyridazin-3-one | 6958-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-benzyl-6-methyl-2,3-dihydropyridazin-3-one
• 英文别名: 2-benzyl-6-methyl-2H-pyridazin-3-one；2-Benzyl-6-methyl-2H-pyridazin-3-on；2-Benzyl-6-methyl-3(2H)-pyridazinone；2-benzyl-6-methylpyridazin-3-one
• CAS: 6958-53-8
• 化学式: C₁₂H₁₂N₂O
• mdl: MFCD00117622
• 分子量: 200.24
• InChiKey: HSGNMNRQMWBCSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-benzyl-6-methyl-2,3-dihydropyridazin-3-one 在 copper diacetate 、 一水合肼 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 25.0h， 生成 methyl 4-[(2-benzyl-6-methyl-3-oxo-2,3-dihydropyridazin-4-yl)amino]-3-methylbenzoate
  参考文献：
  名称：

  EP3459941

  摘要：

  公开号：
• 作为产物：
  描述：

  6-甲基-3(2H)-哒嗪酮 、 溴甲苯 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以2.08 g的产率得到2-benzyl-6-methyl-2,3-dihydropyridazin-3-one
  参考文献：
  名称：

  EP3459941

  摘要：

  公开号：

文献信息

• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same
  申请人：Kondo Katsunori

  公开号：US20080221114A1

  公开（公告）日：2008-09-11

  A compound of the following formula (I): wherein A is a group of the following formula (I-A): wherein X is an oxygen atom or a sulfur atom, R 4 is a hydrogen atom, a C 1-6 alkyl group, or other, R 5 is a hydrogen atom or other; or a heteroaryl group or other optionally substituted with a halogen, a C 1-6 alkyl, a C 1-6 alkoxy, or other; R 1 and R 2 are the same or different and are a hydrogen atom, a C 1-6 alkyl group or other; R 3 is a hydrogen atom, a halogen atom, a C 1-6 alkoxy group, or other; R a and R b are the same or different and are a hydrogen atom or a C 1-6 alkyl group; and n is an integer of 0-5; or a pharmaceutically acceptable acid addition salt thereof, which can selectively act on mitochondrial benzodiazepine receptor and is useful as a medicament for treating/preventing anxiety disorder, depression, epilepsy, dementia, and so on.

  以下化合物的化学式(I)，其中A是以下化学式(I-A)的基团：其中X是氧原子或硫原子，R4是氢原子，C1-6烷基或其他，R5是氢原子或其他；或是杂环芳基或其他，可选择地用卤素，C1-6烷基，C1-6烷氧基或其他取代；R1和R2相同或不同，是氢原子，C1-6烷基或其他；R3是氢原子，卤素原子，C1-6烷氧基或其他；Ra和Rb相同或不同，是氢原子或C1-6烷基；n是0-5的整数；或其药学上可接受的酸加盐，可选择性地作用于线粒体苯二氮䓬受体，用作治疗/预防焦虑症、抑郁症、癫痫、痴呆症等药物。
• PYRROLIDINE DERIVATIVE
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP3459941A1

  公开（公告）日：2019-03-27

  The present invention aims to provide a novel compound which has CGRP receptor antagonist activity and which is useful for the treatment of various diseases mediated by CGRP receptors. That is, the present invention relates to the pyrrolidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. In the formulae, W is ring, X is a carbon atom or the like, Y1 to Y4 are carbon atoms or the like, and R1 to R7 is alkyl or the like. The compounds of the present invention or a pharmaceutically acceptable salt thereof have an excellent CGRP receptor antagonist activity, and thus are useful as agents for the treatment of various diseases mediated by CGRP receptors.

  本发明旨在提供一种新型化合物，该化合物具有 CGRP 受体拮抗剂活性，可用于治疗由 CGRP 受体介导的各种疾病。也就是说，本发明涉及下式（I）所代表的吡咯烷衍生物或其药学上可接受的盐。式中，W为环，X为碳原子或类似物，Y1至Y4为碳原子或类似物，R1至R7为烷基或类似物。本发明的化合物或其药学上可接受的盐具有优异的 CGRP 受体拮抗剂活性，因此可用作治疗由 CGRP 受体介导的各种疾病的药物。
• Pyrrolidine derivative
  申请人：KISSEI PHARMACEUTICAL CO., LTD.

  公开号：US10995084B2

  公开（公告）日：2021-05-04

  The present invention aims to provide a novel compound which has CGRP receptor antagonist activity and which is useful for the treatment of various diseases mediated by CGRP receptors. That is, the present invention relates to the pyrrolidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. In the formulae, W is ring, X is a carbon atom or the like, Y1 to Y4 are carbon atoms or the like, and R1 to R7 is alkyl or the like. The compounds of the present invention or a pharmaceutically acceptable salt thereof have an excellent CGRP receptor antagonist activity, and thus are useful as agents for the treatment of various diseases mediated by CGRP receptors.

  本发明旨在提供一种新型化合物，该化合物具有 CGRP 受体拮抗剂活性，可用于治疗由 CGRP 受体介导的各种疾病。也就是说，本发明涉及下式（I）所代表的吡咯烷衍生物或其药学上可接受的盐。式中，W为环，X为碳原子或类似物，Y1至Y4为碳原子或类似物，R1至R7为烷基或类似物。本发明的化合物或其药学上可接受的盐具有优异的 CGRP 受体拮抗剂活性，因此可用作治疗由 CGRP 受体介导的各种疾病的药物。
• Aldous; Castle, Arzneimittel-Forschung/Drug Research, 1963, vol. 13, p. 878,879,881
  作者：Aldous、Castle

  DOI：——

  日期：——